Riociguat for the treatment of pulmonary hypertension
Tapia-López E, Rey-Ares L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A
Record ID 32016001127
Spanish
Authors' recommendations:
Evidence of moderate methodological quality shows that riociguat, when compared with placebo, improves short-term functional capacity in patients with Functional Class II and III pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
No evidence was found assessing mortality or comparing riociguat with other widely used therapeutic alternatives of proven efficacy, safety and affordable costs.
The clinical practice guidelines reviewed mention its use and recommend to the extent they do with other existing treatments. The public health systems of Scotland, Wales and the United States as well as private U.S. health sponsors cover it.
Its high cost may limit the availability of this treatment.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Enzyme Activators
- Hypertension, Pulmonary
- Pyrazoles
- Pyrimidines
- Pulmonary Arterial Hypertension
- Soluble Guanylyl Cyclase
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.